Pericardial tuberculosis

Summary

Pericardial tuberculosis (MONDO:0005903) is a disease and 2 clinical trials. Top therapeutic interventions include prednisolone. A subtype of extrapulmonary tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pericardial tuberculosis
Mondo ID	MONDO:0005903
EFO	EFO:0007426
MeSH	D010495
DOID	DOID:4962
ICD-11	2135325100
SNOMED CT	67256000
UMLS	C0031049
MedGen	18379
GARD	0024252
Is cancer (heuristic)	no

Also known as: tuberculous pericarditis

Disease family

This is a subtype of extrapulmonary tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › extrapulmonary tuberculosis › pericardial tuberculosis

Related subtypes (12): abdominal tuberculosis, cardiac tuberculosis, central nervous system tuberculosis, gastrointestinal tuberculosis, laryngeal tuberculosis, lymph node tuberculosis, miliary tuberculosis, pleural tuberculosis, skeletal tuberculosis, urogenital tuberculosis, ocular tuberculosis, cutaneous tuberculosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00810849	PHASE3	COMPLETED	A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis
NCT04521803	PHASE2	RECRUITING	High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PREDNISOLONE	4	1